About this trial
Opioids are often added with a local anesthetic to enhance the duration and quality of spinal anesthesia for cesarean delivery patients. However, spinal opioids are associated with a wide variety of side effects such as nausea, vomiting, (N/V) and pruritus (itching). The occurrence of pruritus can vary between 30% and 100% making pruritus the most common side-effect of intrathecal opioids and this rate is even higher in pregnant patients. Pruritus may require treatment which can be ineffective or sometimes reverse the analgesic effect of the opioids. Ondansetron is a safe and very commonly used Serotonin receptor antagonist treatment for local anesthetic opioid-induced pruritus used in pregnancy. The effect of different administration times of ondansetron in reducing pruritus or N/V in cesarean section (CS) cases has not been extensively studied and thus, this prospective study can help guide future clinical management of side effects caused by spinal intrathecal morphine administration.
Eligibility criteria
Qualifiers
American Society of Anesthesiologists (ASA) physical status 1-3
Adult parturient (18 -50 years of age) scheduled to undergo elective cesarean delivery under spinal anesthesia
Patients must be willing and cognitively able to give written informed study consent
Disqualifiers
Patients with an ASA physiological assessment greater than grade 3
Allergies to local anesthetics, opioids, or ondansetron
Coagulopathies precluding provision of spinal anesthesia
Pre-eclampsia with severe features
Trial design
Treatments tested in this trial
- Ondansetron 8mg